Fang Ze-Hao, Zheng Su-Ying, Feng Wei-Ying
School of Medicine, Shaoxing University; Shaoxing People's Hospital, Shaoxing 312000, Zhejiang Province, China.
Department of Hematology, Shaoxing People's Hospital, Shaoxing 312000, Zhejiang Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Jun;31(3):902-906. doi: 10.19746/j.cnki.issn.1009-2137.2023.03.042.
Obesity-associated protein (FTO) is an important m6A demethylase that regulates RNA methylation modification and can promote the proliferation of acute myeloid leukemia(AML) cells. FTO regulates the methylation level of AML through multiple cellular signaling pathways such as FTO/RARA/ASB2, FTO/m6A/CEBPA, and PDGFRB/ERK, and participates in the occurrence, development, treatment and prognosis of AML. At present, studies have found that a variety of inhibitors targeting FTO have shown good anti-leukemia effects, and the study of FTO will provide new ideas for the treatment of AML. This review focus on the mechanism of action of FTO in AML and the research progress of FTO inhibitors in AML.
肥胖相关蛋白（FTO）是一种重要的m6A去甲基化酶，可调节RNA甲基化修饰，并能促进急性髓系白血病（AML）细胞的增殖。FTO通过FTO/RARA/ASB2、FTO/m6A/CEBPA和PDGFRB/ERK等多种细胞信号通路调节AML的甲基化水平，并参与AML的发生、发展、治疗及预后。目前，研究发现多种靶向FTO的抑制剂已显示出良好的抗白血病作用，对FTO的研究将为AML的治疗提供新思路。本文综述聚焦于FTO在AML中的作用机制以及FTO抑制剂在AML中的研究进展。
